. Author manuscript; available in PMC: 2019 Apr 27.

Published in final edited form as: Pharmacogenomics J. 2018 Oct 27;19(3):260–268. doi: 10.1038/s41397-018-0065-x

Table 1.

Sample size and methodological details for trials of methadone or buprenorphine for the treatment of opioid dependence

Study	N	Medication	Length	Abstinence Reinforcement	Dose Limits	Miscellaneous
326–1	1	Methadone	25 weeks	Cocaine and/or opioids	70 mg/day	7 visits/week
326–2	1	Methadone	25 weeks	Cocaine or opioids	100 mg/day	7 visits/week
385	4	Methadone	20 weeks	Opioids	100 mg/day	7 visits/week
020-MTD^a	18	Methadone	46 weeks	None	No ceiling; target dose 100 mg/day	5–7 visits/week
020-BUP^a	25	Buprenorphine	46 weeks	None	No ceiling; target dose 16 mg/day	5 visits/week
020-OBOT^a	19	Buprenorphine	22 weeks	None	24 mg/day	2–3 visits/week
407	11	Buprenorphine	28 weeks	Opioids	24 mg/day	7 visits/week. Randomized to clonidine or placebo for weeks 7–20

Protocol 020 arms: Methadone Maintenance (020-MTD); Buprenorphine Maintenance (020-BUP; Office-Based Therapy (020-OBOT)